Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cell entry of many enveloped viruses occurs by engagement with cellular receptors, followed by internalization into endocytic compartments and pH-induced membrane fusion. A previously unnoticed step of receptor switching was found to be critical during cell entry of two devastating human pathogens: Ebola and Lassa viruses. Our recent studies revealed the functional role of receptor switching to LAMP1 for triggering membrane fusion by Lassa virus and showed the involvement of conserved histidines in this switching, suggesting that other viruses from this family may also switch to LAMP1. However, when we investigated viruses that are genetically close to Lassa virus, we discovered that they cannot bind LAMP1. A crystal structure of the receptor-binding module from Morogoro virus revealed structural differences that allowed mapping of the LAMP1 binding site to a unique set of Lassa residues not shared by other viruses in its family, illustrating a key difference in the cell-entry mechanism of Lassa virus that may contribute to its pathogenicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423696 | PMC |
| http://dx.doi.org/10.1371/journal.ppat.1006337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
pH-induced conformational changes and inhibition of the Lassa virus spike complex.
Cell Host Microbe
August 2025
Department of Chemical and Structural Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel. Electronic address:
Lassa virus (LASV) is a devastating human pathogen with no vaccines and limited therapeutics. The LASV class-I spike complex engages target cells via binding its primary host receptor, matriglycan, followed by macropinocytosis and binding of its secondary receptor, lysosomal-associated membrane protein 1 (LAMP1), to trigger virus fusion. This process occurs across multiple pH-dependent steps, but the molecular events remain largely unknown.
View Article and Find Full Text PDFRobust polyfunctional CD8 and CD4 T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein.
J Gen Virol
September 2025
Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
Lassa virus (LASV) is circulating in rodents in several countries in West Africa and is the causative agent of the zoonotic disease Lassa fever. Several vaccine candidates have been successfully tested in preclinical and clinical research, while no LASV-specific vaccines or antiviral treatments have been licensed to date. Approximately 500,000 human cases of Lassa fever are estimated to occur every year.
View Article and Find Full Text PDFClade I mpox vaccination: strategies for deployment and evaluation.
EBioMedicine
August 2025
Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Electronic address:
Aerostability of Sin Nombre Virus Aerosol Related to Near-Field Transmission.
Pathogens
July 2025
Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center (UNMC), Omaha, NE 68198, USA.
Sin Nombre virus (SNV) is the main causative agent of hantavirus cardiopulmonary syndrome (HCPS) in North America. SNV is transmitted via environmental biological aerosols (bioaerosols) produced by infected deer mice (). It is similar to other viruses that have environmental transmission routes rather than a person-to-person transmission route, such as avian influenza (e.
View Article and Find Full Text PDFLicoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies.
J Genet Eng Biotechnol
September 2025
Dawn of Bioinformatics Limited, Dhaka, Bangladesh; BBA in Management, Bangladesh National University, Gazipur, Bangladesh.
Lassa virus causes a severe hemorrhagic disease referred to as Lassa fever. It exhibits a significant mortality rate among people in West and Central Africa. Currently, there is no vaccine available, and ribavirin is the sole treatment option with significant limitations.
View Article and Find Full Text PDF